Journal article
Altered IgG4 antibody response to repeated mRNA versus recombinant protein SARS-CoV-2 vaccines
R Kalkeri, M Zhu, S Cloney-Clark, JS Plested, A Parekh, D Gorinson, R Cai, S Mahato, P Ramanathan, LC Aurelia, KJ Selva, AM Marchese, L Fries, AW Chung, LM Dunkle
Journal of Infection | Published : 2024
Related Projects (1)
Grants
Funding Acknowledgements
This study was funded by Novavax, Inc. Samples from 2019nCoV-301 (ClinicalTrials.gov: NCT04611802) were included in the present study. 2019nCoV-301 was funded by the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA; contract Operation Warp Speed: Novavax Project Agreement number 1 under Medical CBRN [Chemical, Biological, Radiological, and Nuclear] Defense Consortium base agreement no. 2020-530; Department of Defense no. W911QY20C0077); and the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health. The NIAID provides grant funding to the HIV Vaccine Trials Network (HVTN) Leadership and Operations Center (UM1 AI68614), the HVTN Statistics and Data Management Center (UM1 AI68635), the HVTN Laboratory Center (UM1 AI68618), the HIV Prevention Trials Network Leadership and Operations Center (UM1 AI68619), the AIDS Clinical Trials Group Leadership and Operations Center (UM1 AI68636), and the Infectious Diseases Clinical Research Consortium leadership group (UM1AI148684).Samples from 2019nCoV-307 (ClinicalTrials.gov: NCT05463068) were included in the present study. 2019nCoV-307 was funded by Novavax, Inc. with support from the US BARDA (Contract W15QKN-16-9-1002, Project Number MCDC2011-001).